EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 374 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $809,003,439 | +19.6% | 37,025,329 | +4.6% | 0.02% | +21.1% |
| Q2 2023 | $676,251,742 | -3.8% | 35,387,323 | -2.3% | 0.02% | -9.5% |
| Q1 2023 | $702,917,119 | +26.9% | 36,214,174 | +4.9% | 0.02% | +23.5% |
| Q4 2022 | $553,865,917 | +4.2% | 34,530,294 | +1.9% | 0.02% | -5.6% |
| Q3 2022 | $531,477,000 | -23.9% | 33,895,320 | +1.0% | 0.02% | -18.2% |
| Q2 2022 | $698,653,000 | -6.3% | 33,556,731 | +2.0% | 0.02% | +10.0% |
| Q1 2022 | $745,493,000 | +26.3% | 32,884,561 | +1.9% | 0.02% | +33.3% |
| Q4 2021 | $590,029,000 | -12.5% | 32,277,378 | +1.2% | 0.02% | -21.1% |
| Q3 2021 | $674,514,000 | +18.3% | 31,907,047 | +2.0% | 0.02% | +18.8% |
| Q2 2021 | $570,193,000 | -21.4% | 31,294,943 | -2.5% | 0.02% | -23.8% |
| Q1 2021 | $725,369,000 | +15.1% | 32,110,132 | +2.3% | 0.02% | +5.0% |
| Q4 2020 | $629,948,000 | -15.9% | 31,387,574 | +2.5% | 0.02% | -28.6% |
| Q3 2020 | $748,816,000 | +0.1% | 30,626,404 | -2.8% | 0.03% | -6.7% |
| Q2 2020 | $747,843,000 | +43.6% | 31,501,414 | +4.2% | 0.03% | +20.0% |
| Q1 2020 | $520,647,000 | -7.2% | 30,234,952 | -5.0% | 0.02% | +13.6% |
| Q4 2019 | $560,917,000 | +3.2% | 31,834,126 | +3.6% | 0.02% | -4.3% |
| Q3 2019 | $543,551,000 | -17.1% | 30,735,203 | +0.2% | 0.02% | -17.9% |
| Q2 2019 | $655,713,000 | -10.8% | 30,683,870 | -0.6% | 0.03% | -15.2% |
| Q1 2019 | $734,839,000 | +22.1% | 30,875,633 | +1.0% | 0.03% | +10.0% |
| Q4 2018 | $601,600,000 | +12.8% | 30,584,751 | +1.6% | 0.03% | +30.4% |
| Q3 2018 | $533,265,000 | -14.5% | 30,094,004 | +3.8% | 0.02% | -20.7% |
| Q2 2018 | $624,024,000 | +72.8% | 28,997,375 | +77.8% | 0.03% | +70.6% |
| Q1 2018 | $361,211,000 | -27.2% | 16,307,466 | -0.1% | 0.02% | -29.2% |
| Q4 2017 | $496,183,000 | +24.4% | 16,321,767 | -0.8% | 0.02% | +20.0% |
| Q3 2017 | $398,797,000 | +6.7% | 16,458,727 | +8.5% | 0.02% | 0.0% |
| Q2 2017 | $373,718,000 | -10.0% | 15,173,328 | -20.8% | 0.02% | -13.0% |
| Q1 2017 | $415,099,000 | +48966.1% | 19,155,466 | +33678.5% | 0.02% | +2200.0% |
| Q4 2016 | $846,000 | +4.3% | 56,709 | -10.5% | 0.00% | 0.0% |
| Q3 2016 | $811,000 | +187.6% | 63,397 | +76.1% | 0.00% | – |
| Q2 2016 | $282,000 | +370.0% | 35,993 | +138.7% | 0.00% | – |
| Q1 2016 | $60,000 | +62.2% | 15,077 | +128.6% | 0.00% | – |
| Q4 2015 | $37,000 | +37.0% | 6,596 | +37.9% | 0.00% | – |
| Q3 2015 | $27,000 | +42.1% | 4,784 | -6.1% | 0.00% | – |
| Q2 2015 | $19,000 | +11.8% | 5,095 | -22.1% | 0.00% | – |
| Q1 2015 | $17,000 | +88.9% | 6,542 | 0.0% | 0.00% | – |
| Q4 2014 | $9,000 | -10.0% | 6,542 | 0.0% | 0.00% | – |
| Q3 2014 | $10,000 | -47.4% | 6,542 | +19.1% | 0.00% | – |
| Q2 2014 | $19,000 | 0.0% | 5,495 | 0.0% | 0.00% | – |
| Q1 2014 | $19,000 | -98.7% | 5,495 | -97.7% | 0.00% | -100.0% |
| Q4 2013 | $1,466,000 | +4481.2% | 239,095 | +4251.1% | 0.00% | – |
| Q3 2013 | $32,000 | +28.0% | 5,495 | 0.0% | 0.00% | – |
| Q2 2013 | $25,000 | – | 5,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |